Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04317105 |
|
Recruitment Status :
Recruiting
First Posted : March 23, 2020
Last Update Posted : March 8, 2023
|
Sponsor:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
National Cancer Institute (NCI)
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This phase I/II trial studies the side effects and best dose of copanlisib when given together with nivolumab and ipilimumab and to see how well they work in treating patients with solid cancers that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and have changes in PIK3CA and PTEN genes. Copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The addition of copanlisib to usual immunotherapy may work better in treating patients with solid cancers compared to usual immunotherapy alone.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Advanced Malignant Solid Neoplasm Metastatic Malignant Solid Neoplasm Unresectable Malignant Solid Neoplasm | Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Drug: Copanlisib Hydrochloride Biological: Ipilimumab Biological: Nivolumab Procedure: X-Ray Imaging | Phase 1 Phase 2 |
Show detailed description
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 102 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase I/II Biomarker Driven Combination Trial of Copanlisib and Immune Checkpoint Inhibitors in Patients With Advanced Solid Tumors |
| Actual Study Start Date : | April 15, 2020 |
| Estimated Primary Completion Date : | December 31, 2023 |
| Estimated Study Completion Date : | December 31, 2023 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Trial I (copanlisib, nivolumab)
Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15 of cycle 1. Beginning in cycle 2, patients also receive nivolumab IV over 60 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray and/or CT scan, as well as a tumor biopsy during screening and on study. Patients also undergo blood sample collection on study.
|
Procedure: Biopsy
Undergo a tumor biopsy
Other Names:
Procedure: Biospecimen Collection Undergo blood sample collection
Other Names:
Procedure: Computed Tomography Undergo a CT scan
Other Names:
Drug: Copanlisib Hydrochloride Given IV
Other Names:
Biological: Nivolumab Given IV
Other Names:
Procedure: X-Ray Imaging Undergo an x-ray
Other Names:
|
|
Experimental: Trial II (copanlisib, nivolumab, ipilimumab)
Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15 of cycle 1. Beginning in cycle 2, patients also receive nivolumab IV over 60 minutes on day 1 and ipilimumab IV over 90 minutes every 8 weeks for 4 doses. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray and/or CT scan, as well as a tumor biopsy during screening and on study. Patients also undergo blood sample collection on study.
|
Procedure: Biopsy
Undergo a tumor biopsy
Other Names:
Procedure: Biospecimen Collection Undergo blood sample collection
Other Names:
Procedure: Computed Tomography Undergo a CT scan
Other Names:
Drug: Copanlisib Hydrochloride Given IV
Other Names:
Biological: Ipilimumab Given IV
Other Names:
Biological: Nivolumab Given IV
Other Names:
Procedure: X-Ray Imaging Undergo an x-ray
Other Names:
|
Primary Outcome Measures :
- Incidence of adverse events and serious adverse events [ Time Frame: At 30 days after last dose of study drug and every 3-6 months for up to 2 years ]Adverse events and serious adverse events will be graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
- Incidence of dose limiting toxicities (DLTs) [ Time Frame: Up to first 2 cycles (each cycle is 28 days) ]Toxicities will be graded using NCI CTCAE version 5.0.
Secondary Outcome Measures :
- Objective response (OR) rate (complete response [CR] + partial response [PR]) [ Time Frame: Up to 2 years post-treatment ]Will estimate OR rate with 95% confidence intervals. Inferences and estimation are based on the exact binomial test.
- Clinical benefit rate (OR + stable disease [SD] > 6 months) [ Time Frame: Up to 2 years post-treatment ]
- Progression free survival (PFS) [ Time Frame: Until disease progression, start of a new cancer therapy, or up to 2 years after the last dose of study drugs, whichever comes first ]Will use the Kaplan-Meier method to estimate PFS.
- Overall survival (OS) [ Time Frame: Until disease progression, start of a new cancer therapy, or up to 2 years after the last dose of study drugs, whichever comes first ]Will use the Kaplan-Meier method to estimate OS.
Other Outcome Measures:
- Change in tumor immune microenvironment with copanlisib alone and with combination of copanlisib, nivolumab and ipilimumab [ Time Frame: Baseline up to 2 years post-treatment ]
- Change in circulating cytokines with copanlisib alone and with combination of copanlisib, nivolumab and ipilimumab [ Time Frame: Baseline up to 2 years post-treatment ]
- Correlation of immuno-modulatory changes with presence or absence of OR to the triplet combination [ Time Frame: Up to 2 years post-treatment ]Will assess immuno-modulatory changes (e.g., change in proportion of cytotoxic T cells, regulatory T cells and memory T cells) associated with copanlisib monotherapy as well as with triplet combination using paired t-tests or Wilcoxon signed rank tests. Will also determine correlation between treatment induced immunomodulatory changes with presence or absence of OR using paired t-tests or Wilcoxon signed rank tests.
- Correlation of molecular alterations in the PI3K-AKT pathway (PIK3CA mutation and PTEN loss) with presence or absence of OR to the combination of copanlisib with nivolumab and ipilimumab [ Time Frame: Up to 2 years post-treatment ]Will further correlate the presence or absence of molecular alterations in the PI3K-AKT pathway as well as other mutations with presence or absence of OR using Chi-square test.
- Correlation of change in expression of pharmacodynamics markers downstream of PI3K inhibition and change in expression of genes involved in alternate signaling pathways with OR to treatment [ Time Frame: Up to 2 years post-treatment ]Changes in expression of pharmacodynamics markers downstream of PI3K inhibition and genes involved in alternate signaling pathways will be correlated with presence or absence of OR using paired t-tests or Wilcoxon signed rank tests.
- Correlation of mutations not associated with PI3K-AKT pathway with presence and absence of OR to treatment [ Time Frame: Up to 2 years post-treatment ]Will further correlate the presence or absence of molecular alterations not associated with the PI3K-AKT pathway with presence or absence of OR using Chi-square test.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients must have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative measures do not exist or are no longer effective
- Patients must be >= 4 weeks beyond treatment with any chemotherapy or other investigational therapy to include hormonal, biological, or targeted agents; or at least 5 half-lives from hormonal, biological, or targeted agents, whichever is shorter at the time of treatment initiation
- Age >= 18 years. Because no dosing or adverse event data are currently available on the use of copanlisib in combination with nivolumab (and ipilimumab) in patients < 18 years of age, children are excluded from this study, but will be eligible for future pediatric trials
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
- Absolute neutrophil count (ANC) >= 1,500 /mcL
- Platelets >= 100,000 / mcL
- Hemoglobin >= 9 g/dL
- Serum creatinine =< 1.5 x upper limit of normal (ULN) OR measured or calculated creatinine clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or creatine clearance [CrCl]) >= 60 mL/min for subject with creatinine levels > 1.5 x institutional ULN (creatinine clearance should be calculated per institutional standard)
- Serum total bilirubin =< 1.5 x ULN OR direct bilirubin =< ULN for subjects with total bilirubin levels > 1.5 x ULN
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN OR =< 5 x ULN for subjects with liver metastases
- International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN unless subject is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants
- Activated partial thromboplastin time (aPTT) =< 1.5 x ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
- Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
- Glycosylated hemoglobin (HbA1c) =< 8.5% at screening
- Women of child-bearing potential MUST have a negative serum or urine human chorionic gonadotropin (HCG) test within 24 hours of study enrollment unless prior tubal ligation (>= 1 year before screening), total hysterectomy or menopause (defined as 12 consecutive months of amenorrhea). Patients should not become pregnant or breastfeed while on this study. Sexually active patients must agree to use dual contraception for the duration of study participation and for 7 months after the last dose of study treatment for women of childbearing potential and 5 months for men with partners that are women of childbearing potential
- Patients need to have biopsiable disease to enroll on Trial 1 (copanlisib + nivolumab)
- Patients in dose escalation and expansion of all arms must have actionable mutations in either PIK3CA hotspot (E542, E545, or H1047 are accepted) or PTEN (except for specific wild type cohorts). Local testing in Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory will be accepted. Only mutations that have been recognized as actionable by the MD Anderson Precision Oncology Decision Support (PODS) team will be accepted
- Ability to understand and the willingness to sign a written informed consent document
- Patients who have previously received PD-1/PD-L1/PI3K inhibitors will be eligible for this study
Exclusion Criteria:
- Patients who are receiving any other investigational agents
- Pregnant or breastfeeding women will be excluded from participation in this trial, as there is no significant clinical information regarding the effects of copanlisib, nivolumab, and ipilimumab on a fetus or newborn infant
- Known active hepatitis B or hepatitis C infection. All patients must be screened for hepatitis B virus (HBV) and hepatitis C virus (HCV) up to 28 days prior to study drug start using the routine hepatitis virus lab panel. Patients positive for hepatitis B virus surface antigen (HBsAg) and/or hepatitis B virus core antibody (HBcAb) will be eligible if they are negative for HBV DNA, these patients should receive prophylactic antiviral therapy. Patients positive for anti-HCV antibody will be eligible if they are negative for HCV RNA
-
Human immunodeficiency virus (HIV)-infected (HIV1/2 antibody-positive) patients may participate IF they meet all the following eligibility requirements:
- They must be on an anti-retroviral regimen with evidence of at least two undetectable viral loads within the past 6 months on this same regimen; the most recent undetectable viral load must be within the past 12 weeks
-
They must have a CD4 count >= 250 cells/mcL over the past 6 months on this same anti-retroviral regimen and must not have had a CD4 count < 200 cells/ mcL over the past 2 years, unless it was deemed related to the cancer and/or chemotherapy-induced bone marrow suppression
- For patients who have received chemotherapy in the past 6 months, a CD4 count < 250 cells/mcL during chemotherapy is permitted as long as viral loads were undetectable during this same chemotherapy
- They must have an undetectable viral load and a CD4 count >= 250 cells/mcL within 7 days of enrollment
- They must not be currently receiving prophylactic therapy for an opportunistic infection and must not have had an opportunistic infection within the past 6 months
- Active infection requiring intravenous (IV) antibiotics or other uncontrolled intercurrent illness requiring hospitalization
- Active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids. Exceptions include vitiligo, type I diabetes mellitus, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids, Sjogren's syndrome
- Inability to comply with the study and follow-up procedures
- History of cerebrovascular accident (CVA), myocardial infarction, or unstable angina within the previous 6 months before starting therapy
- Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone curative therapy, or in situ cervical cancer
- Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the trial
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least 4 weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability
-
Patients with HbA1c > 8.5%
- Note: For patients with newly diagnosed diabetes mellitus that cannot meet protocol requirements, a single re-screening (which includes all screening procedures) should be performed when the patient's diabetes is controlled and can meet protocol eligibility requirement for HbA1c
- History of any clinically significant drug allergy or hypersensitivity to compounds of similar chemical or biologic composition to copanlisib, PI3K inhibitors, nivolumab, and ipilimumab (such as anaphylaxis or hepatotoxicity)
- Has known history of psoriasis even if not active at the time given may pose additional risks of immune activation with the combination regimen
- Patients with live vaccines and live, attenuated vaccines (prohibited for 30 days prior to study agents, during the study, and for 100 days after the last dose of study drug). Patients with inactivated vaccines are permitted
-
Copanlisib is primarily metabolized by CYP3A4. Therefore, the concomitant use of strong inhibitors of CYP3A4 (e.g. ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir, nelfinavir, and saquinavir) and strong inducers of CYP3A4 (e.g. rifampin, phenytoin, carbamazepine, phenobarbital, St. John's wort) is not permitted from 14 days prior to enrollment until the end of the study. Other medications that are prohibited while on copanlisib treatment include:
- Herbal medications/preparations (except vitamins)
- Anti-arrhythmic therapy other than beta blockers or digoxin
- Patients will be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). A brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted. The use of corticosteroids as antiemetics prior to copanlisib administration will not be allowed
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04317105
Locations
| United States, Massachusetts | |
| Dana-Farber Cancer Institute | Active, not recruiting |
| Boston, Massachusetts, United States, 02215 | |
| United States, Texas | |
| University of Texas at Austin | Recruiting |
| Austin, Texas, United States, 78712 | |
| Contact: Site Public Contact 512-232-1543 irb@austin.utexas.edu | |
| Principal Investigator: Kyaw L. Aung | |
| University of Texas Medical Branch | Recruiting |
| Galveston, Texas, United States, 77555-0565 | |
| Contact: Site Public Contact 409-772-1950 clinical.research@utmb.edu | |
| Principal Investigator: Bagi R. Jana | |
| M D Anderson Cancer Center | Recruiting |
| Houston, Texas, United States, 77030 | |
| Contact: Site Public Contact 877-632-6789 askmdanderson@mdanderson.org | |
| Principal Investigator: Timothy A. Yap | |
| United States, Virginia | |
| Virginia Commonwealth University/Massey Cancer Center | Recruiting |
| Richmond, Virginia, United States, 23298 | |
| Contact: Site Public Contact CTOclinops@vcu.edu | |
| Principal Investigator: Andrew Poklepovic | |
| Canada, Ontario | |
| University Health Network-Princess Margaret Hospital | Recruiting |
| Toronto, Ontario, Canada, M5G 2M9 | |
| Contact: Site Public Contact 416-946-4501 clinical.trials@uhn.on.ca | |
| Principal Investigator: Philippe L. Bedard | |
Sponsors and Collaborators
National Cancer Institute (NCI)
Investigators
| Principal Investigator: | Timothy A Yap | University of Texas MD Anderson Cancer Center LAO |
| Responsible Party: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT04317105 |
| Other Study ID Numbers: |
NCI-2020-01917 NCI-2020-01917 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) NCI10221 10221 ( Other Identifier: University of Texas MD Anderson Cancer Center LAO ) 10221 ( Other Identifier: CTEP ) UM1CA186688 ( U.S. NIH Grant/Contract ) |
| First Posted: | March 23, 2020 Key Record Dates |
| Last Update Posted: | March 8, 2023 |
| Last Verified: | January 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page. |
| URL: | https://grants.nih.gov/policy/sharing.htm |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Neoplasms Nivolumab Ipilimumab Antineoplastic Agents, Immunological |
Antineoplastic Agents Immune Checkpoint Inhibitors Molecular Mechanisms of Pharmacological Action |